



# CLINICAL EXPERIENCE WITH BIOSIMILAR INFLIXIMAB\*



**KEY:**  
 ○ BIOLOGICS INCLUDING BIOSIMILAR MEDICINES  
 ● BIOSIMILAR MEDICINES

## CASE STUDIES

🇮🇹 ITALY 🇭🇺 HUNGARY




Source: 3

## BIOSIMILAR MEDICINES: INCREASED OPTIONS FOR PHYSICIANS

### MORE CHOICE OF MODERN TREATMENTS


Source: 1 and 2

### MAJOR THERAPY AREAS



Source: 1

🇬🇧 UK SOUTHAMPTON



Source: 4

SOURCE 1: Adapted from European Medicines Agency website ([www.ema.europa.eu/ema](http://www.ema.europa.eu/ema)). SOURCE 2: Biopharmaceutical benchmarks 2014. G. Walsh, volumen 32, number 10, October 2014. Nature Biotechnology

SOURCE 3: Adapted from Annese V. Findings of prosit - Bid study. AOU Careggi, Florence. June 2016. Presentation at European Commission Stakeholder event on biosimilar medicines products ([link](#))

Adapted from Gece k, Hungarian experience with the use of biosimilar Infliximab in IBD. Semmelweis University. First department of medicine. Budapest. June 2016. Presentation at European Commission Stakeholder event on biosimilar medicines products. ([link](#))

SOURCE 4: Adapted from Cumming F. Experience of biosimilar Infliximab - University hospital Southampton NHS Foundation Trust.

For more information please see consensus information paper Q&A physicians [ec.europa.eu/docsroom/documents/8242](http://ec.europa.eu/docsroom/documents/8242)

\* INFLIXIMAB IS INDICATED IN THE FOLLOWING THERAPEUTIC AREAS: RHEUMATOID ARTHRITIS; CROHN'S DISEASE; ULCERATIVE COLITIS; PSORIASIS, PSORIATIC ARTHRITIS; ANKYLOSING SPONDYLITIS (ADAPTED FROM RESPECTIVE EPAR)